Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke [Basic Sciences]

Conclusions—Blood occludin may be a clinically viable biomarker for evaluating BBB damage during ischemia/reperfusion. NBO therapy has the potential to reduce blood occludin, protect BBB, and improve outcome in AIS patients with intravenous tPA thrombolysis.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02974283.

Source: Stroke - September 25, 2017 Category: Neurology Authors: Shuhai Shi, Zhifeng Qi, Qingfeng Ma, Rong Pan, Graham S. Timmins, Yongmei Zhao, Wenjuan Shi, Yunzhou Zhang, Xunming Ji, Ke Jian Liu Tags: Biomarkers, Clinical Studies, Translational Studies, Blood-Brain Barrier, Ischemic Stroke Original Contributions Source Type: research